184 related articles for article (PubMed ID: 18473856)
21. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
22. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S
Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746
[TBL] [Abstract][Full Text] [Related]
23. [CPT-11 (irinotecan)--evidence from molecular and pharmacological studies and clinical applications].
Isobe T; Ishikawa N; Oguri T
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1267-78. PubMed ID: 10945026
[TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.
O'Leary JJ; Shapiro RL; Ren CJ; Chuang N; Cohen HW; Potmesil M
Clin Cancer Res; 1999 Jan; 5(1):181-7. PubMed ID: 9918217
[TBL] [Abstract][Full Text] [Related]
25. Irinotecan (CPT-11): pharmacology and clinical applications.
Masuda N; Kudoh S; Fukuoka M
Crit Rev Oncol Hematol; 1996 Sep; 24(1):3-26. PubMed ID: 8869796
[No Abstract] [Full Text] [Related]
26. Topoisomerase I inhibition: a new target or new missiles?
Verweij J; Schellens JH
Ann Oncol; 1995 Feb; 6(2):102-4. PubMed ID: 7786815
[No Abstract] [Full Text] [Related]
27. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
28. CPT-11. The European experience.
Armand JP; Terret C; Couteau C; Rixe O
Ann N Y Acad Sci; 1996 Dec; 803():282-91. PubMed ID: 8993522
[TBL] [Abstract][Full Text] [Related]
29. Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise.
Khaiwa N; Maarouf NR; Darwish MH; Alhamad DWM; Sebastian A; Hamad M; Omar HA; Orive G; Al-Tel TH
Eur J Med Chem; 2021 Nov; 223():113639. PubMed ID: 34175539
[TBL] [Abstract][Full Text] [Related]
30. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
Ohe Y; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Kojima A; Kunikane H; Okamoto H; Karato A; Ohmatsu H
J Natl Cancer Inst; 1992 Jun; 84(12):972-4. PubMed ID: 1321253
[No Abstract] [Full Text] [Related]
31. UGT1A and irinotecan toxicity: keeping it in the family.
Hoskins JM; McLeod HL
J Clin Oncol; 2009 May; 27(15):2419-21. PubMed ID: 19364959
[No Abstract] [Full Text] [Related]
32. Insights into the pharmacokinetics and pharmacodynamics of irinotecan.
Ratain MJ
Clin Cancer Res; 2000 Sep; 6(9):3393-4. PubMed ID: 10999719
[No Abstract] [Full Text] [Related]
33. Novel camptothecin derivatives as topoisomerase I inhibitors.
Basili S; Moro S
Expert Opin Ther Pat; 2009 May; 19(5):555-74. PubMed ID: 19441934
[TBL] [Abstract][Full Text] [Related]
34. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
35. Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond.
Rothenberg ML
Oncologist; 2001; 6(1):66-80. PubMed ID: 11161230
[TBL] [Abstract][Full Text] [Related]
36. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
Svenson S; Wolfgang M; Hwang J; Ryan J; Eliasof S
J Control Release; 2011 Jul; 153(1):49-55. PubMed ID: 21406204
[TBL] [Abstract][Full Text] [Related]
37. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
[TBL] [Abstract][Full Text] [Related]
38. Comment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE).
Dodds HM; Rivory LP
Br J Pharmacol; 2001 Sep; 134(2):448-50. PubMed ID: 11564665
[No Abstract] [Full Text] [Related]
39. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
40. Modulation of camptothecin analogs in the treatment of cancer: a review.
Kehrer DF; Soepenberg O; Loos WJ; Verweij J; Sparreboom A
Anticancer Drugs; 2001 Feb; 12(2):89-105. PubMed ID: 11261892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]